tert-butyl (3E)-3-[(tert-butoxycarbonyl)hydrazono]piperidine-1-carboxylate | 1305274-91-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl (3E)-3-[(tert-butoxycarbonyl)hydrazono]piperidine-1-carboxylate
• 英文别名: tert-butyl (3E)-3-[(2-methylpropan-2-yl)oxycarbonylhydrazinylidene]piperidine-1-carboxylate
• CAS: 1305274-91-2
• 化学式: C₁₅H₂₇N₃O₄
• 分子量: 313.397
• InChiKey: AKBAOJZFTCJKLJ-LFIBNONCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  80.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  肼基甲酸叔丁酯 、 N-叔丁氧羰基-3-哌啶酮 在 正庚烷 作用下， 以 甲苯 为溶剂， 反应 4.0h， 以to give 15 g (95%) of the title compound as a beige solid的产率得到tert-butyl (3E)-3-[(tert-butoxycarbonyl)hydrazono]piperidine-1-carboxylate
  参考文献：
  名称：

  Tricyclic pyrazol amine derivatives

  摘要：

  本发明涉及式(I*)化合物作为Pi3k抑制剂，用于治疗自身免疫性疾病、炎症性疾病、多发性硬化症和其他疾病，如癌症。

  公开号：

  US09073940B2

文献信息

• [EN] TRICYCLIC PYRAZOL AMINE DERIVATIVES<br/>[FR] DÉRIVÉS TRICYCLIQUES DE PYRAZOLAMINE
  申请人：MERCK SERONO SA

  公开号：WO2011058149A1

  公开（公告）日：2011-05-19

  This invention relates to compounds of Formula (I*) as Pi3k inhibitors for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other diseases like cancers.

  这项发明涉及到 Formula (I*) 的化合物作为 Pi3k 抑制剂，用于治疗自身免疫疾病、炎症性疾病、多发性硬化等疾病，以及癌症等其他疾病。
• [EN] 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS<br/>[FR] DÉRIVÉS DE 1-HÉTÉROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE ET LEURS UTILISATIONS À TITRE DE MODULATEURS DE PDE9A
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009121919A1

  公开（公告）日：2009-10-08

  The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, Formula (I) with Hc is a mono-, bi- or tricyclic heterocyclyl group, the ring members of which are carbon atoms and at least 1, preferably 1, 2 or 3, heteroatom(s), which are selected from the group of nitrogen, oxygen and sulphur, which is in the form of -S(O)r - with r being 0, 1 or 2, and - said heterocyclyl group is or comprises 1 non-aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member and - said heterocyclyl group is bound to the scaffold by said 1 non- aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.

  该发明涉及新型1,6-二取代吡唑吡嘧啶酮，化学式（I），其中Hc是一个单环、双环或三环杂环基团，其环成员为碳原子和至少1个，优选1个、2个或3个来自氮、氧和硫的杂原子，其以-S(O)r-的形式存在，其中r为0、1或2，所述杂环基团是或包括1个非芳香、饱和或部分不饱和的单环环，其中至少包含1个杂原子作为环成员，所述杂环基团通过所述至少包含1个杂原子作为环成员的非芳香、饱和或部分不饱和的单环环与支架相结合。根据该发明的一个方面，新化合物用于制造药物，特别是用于治疗感知、注意力、学习或记忆缺陷相关疾病的药物。新化合物还用于制造治疗阿尔茨海默病的药物。
• 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATES AND THEIR USE AS PDE9A MODULATORS
  申请人：Giovannini Riccardo

  公开号：US20110184000A1

  公开（公告）日：2011-07-28

  The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, Formula (I) with is a mono-, bi- or tri-cyclic heterocyclyl group, the ring members of which are carbon atoms and at least 1, preferably 1, 2 or 3, heteroatom(s), which are selected from the group of nitrogen, oxygen and sulphur, which is in the form of —S(O) r — with r being 0, 1 or 2, and—said heterocyclyl group is or comprises 1 non-aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member and—said heterocyclyl group is bound to the scaffold by said 1 non-aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.

  本发明涉及一种新型的1,6-二取代吡唑嘧啶酮（Formula (I)），其中为单、双或三环杂环基，其环成员为碳原子，至少1个，优选1、2或3个杂原子，所述杂原子选自氮、氧和硫的群体，并以—S(O)r—的形式出现，其中r为0、1或2，所述杂环基是或包含1个非芳香、饱和或部分不饱和的单环环，其中至少包含1个杂原子作为环成员，并且所述杂环基通过所述1个非芳香、饱和或部分不饱和的单环环，其中至少包含1个杂原子作为环成员，与支架结合。根据本发明的一方面，新化合物用于制造药物，特别是用于治疗感知、注意力、学习或记忆缺陷的药物。新化合物也用于制造治疗阿尔茨海默病的药物。
• NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS
  申请人：GIOVANNINI Riccardo

  公开号：US20110082137A1

  公开（公告）日：2011-04-07

  The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones of formula (I), in which Hc is a tetrahydropyranyl-group and R 1 is the group V—W−*, whereby V and W independently of each other may be an aryl group or an heteroaryl group, which independently of each other may optionally be substituted. According to one aspect of the invention the new compounds are for use as medicaments or for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments and/or for use in the treatment of e.g. Alzheimer's disease, in particular for cognitive impairment associated with Alzheimer's disease.

  本发明涉及一种新型的1,6-二取代吡唑嘧啶酮化合物，其化学式为（I），其中Hc为四氢吡喃基团，R1为V-W−*基团，其中V和W各自独立地可以是芳基基团或杂环基团，可以选择地进行取代。根据本发明的一个方面，这些新化合物可用作药物或制药用途，特别是用于治疗与感知、注意力、学习或记忆缺陷有关的疾病。这些新化合物还可用于制药或用于治疗例如阿尔茨海默病等疾病，特别是用于与阿尔茨海默病相关的认知障碍的治疗。
• TRICYCLIC PYRAZOL AMINE DERIVATIVES
  申请人：Gaillard Pascale

  公开号：US20120238545A1

  公开（公告）日：2012-09-20

  This invention relates to compounds of Formula (I*) as Pi3k inhibitors for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other diseases like cancers.

  本发明涉及式(I*)化合物，作为Pi3k抑制剂，用于治疗自身免疫性疾病、炎症性疾病、多发性硬化和其他疾病，如癌症。